Azitra Inc., a Farmington, Conn.-based clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome, closed a $14m Series A financing.
The round, which brought total funding raised to date to $17m, was led by KdT Ventures with participation from existing investor Bios Partners, Connecticut Innovations and Godfrey Capital.
The company intends to use the funds to expand the management team and to advance its medical dermatology products in the clinic.
Founded in 2014 and led by Richard Andrews, President and Chief Executive Officer, Azitra is focused on treating skin disease by combining microbiome with molecular genetics.
The company’s product pipeline includes medical dermatology products to treat cancer therapy-associated skin rashes, Netherton syndrome, atopic dermatitis and ichthyosis vulgaris.